Fritextsökning
Innehållstyper
-
Aurevia
-
Spatial Biology Studies in Lung Tissue using Spectral Microscopy
Spectral imaging with the ZEISS LSM 980 laser scanning confocal enables more complex studies of cell-cell interactions and locations in immunology research.
-
AI detects tumor disease – via voice recording
A short voice recording along with facial images – both analyzed with an AI algorithm – can make it possible to detect the rare tumour disease acromegaly and in...
-
Oncozenges tablett mot munsmärta utlicensieras för Gulf-regionen
Oncozenge har ingått ett licensavtal med Dubaibaserade Avernus Pharma om kommersialisering i Gulf-regionen av Bupizenge, en sugtablett under utveckling för beha...
-
Wusson Accelerator AB
-
Japansk läkemedelsjätte flyttar till Forskaren
Ännu ett stort läkemedelsbolag flyttar in i Forskaren i Hagastaden.
-
Positiva data för vaccin i pulverform – ”Fungerar lika bra”
En ny studie indikerar att ett nytt influensavaccin, som utvecklas av Abera Bioscience i samarbete med Orexo, fungerar både som sprej och pulver.
-
Faster development of reliable sample handling
to integrate into the customer's platform – with standard components from Festo, a PerkinElmer® JANUS G3 workstation and a modified rotary gripper module. This ...
-
The Swedish Foundation for Strategic Research
-
Gustaf Salford får gå från Elekta – ”ledde företaget genom pandemin”
Gustaf Salford avgår som vd för Elekta. Styrelsen har nu inlett ”internationell rekryteringsprocess” för att hitta hans ersättare.
-
From powder to implant
Quality assurance for additively manufactured implants.
-
Automated opening and closing of sample vials
From technical requirements to a suitable solution
-
Enhance your expertise with your measuring software
Discover the training options in our ZEISS Metrology Portal.
-
Uppsala-based company wins important patent dispute – but the decision is subject to appeal
A US district court has ruled in favour of Orexo in a dispute over the patent protecting the Swedish company’s drug Zubsolv, developed for treating patients wit...
-
Astra Zeneca i Danmark värvar svenskt
Astra Zeneca i Danmark har rekryterat svenska Emma Collijn som chef för de respiratoriska och immunologiska terapiområdena i affärsenheten för biofarmaceutiska produkter.
-
Automated nitrogen analysis reduces costs per sample
N-Realizer analytical system from C. Gerhardt increases productivity with valve block from Festo
-
Sobi announces agreement with Enable Injections
Swedish biopharma Sobi has entered into an international development and distribution agreement with US drug delivery company Enable Injections.
-
Business Sweden: ”Bolag har mycket att tillföra inom datadriven precisionsmedicin”
Datadriven precisionsmedicin har potentialen att lösa stora problem inom sjukvården. Det skriver Business Sweden i en ny rapport på ämnet.
-
Collaboration in laboratory automation
The Dutch company Synchron Lab Automation developed an automated DNA extraction system with high throughput, working very closely together with Festo. As a resu...
-
Carl Borrebaeck – professor and serial entrepreneur with a taste for speed
Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borreb...
-
MSD discontinues two Keytruda trials
MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.
-
Double up for Korbinian Löbmann
This year, Korbinian Löbmann will moderate the New Updates in Drug Formulation & Bioavailability meeting in Copenhagen for the fifth time. Furthermore, he will ...
-
Marie Gårdmark: “What to expect from Trump’s second term?”
One may complain about the complex multinational system in EU, but it gives us some predictability that cannot be easily overturned by different member states p...
-
High-tech companies are increasingly focusing on health
Tech companies have been taking an interest in healthcare for many years, and this interest seems to be increasing. “It’s not a sudden shift in trend, it’s more...